Virtu Financial’s Neumora Therapeutics NMRA Stock Holding History

Virtu Financial’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,489	Closed	-$50K	–	2032
2026 Q1	$50K	Sell	25,489 -71,919	-74%	-$186K	﹤0.01%	1289
2025 Q4	$174K	Buy	97,408 +80,189	+466%	+$176K	0.01%	1068
2025 Q3	$31K	Buy	+17,219	New	+$27.8K	﹤0.01%	1223
2025 Q2	–	Sell	-39,676	Closed	-$40K	–	1856
2025 Q1	$40K	Buy	+39,676	New	+$67.9K	﹤0.01%	1040

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Virtu Financial's NMRA Position: Q2 2026 in Review

Virtu Financial sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 25,489 shares — an estimated $50K sold.

Virtu Financial first reported a position in NMRA in Q1 2025 and held it in 4 quarters. The position peaked at $174K in Q4 2025. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

Virtu Financial reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 25,489 Neumora Therapeutics shares in Q2 2026, an estimated $50K.
Virtu Financial first reported a position in Neumora Therapeutics in Q1 2025 and held it in 4 quarters.
Virtu Financial's Neumora Therapeutics position peaked at $174K in Q4 2025.
113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.